Articles

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma

Christian U Blank, Minke W Lucas, Richard A Scolyer, et al. N Engl J Med. 2024 Nov 7;391(18):1696-1708

In phase 1-2 trials in patients with resectable, macroscopic stage III melanoma, neoadjuvant immunotherapy was more efficacious than adjuvant immunotherapy. A total of 423 patients underwent randomization. At a median follow-up of 9.9 months, the estimated 12-month event-free survival was 83.7% in the neoadjuvant group... Read More

24 Mar, 2026

Nonoperative Management of Mismatch Repair-Deficient Tumors

Andrea Cercek, Michael B Foote, Benoit Rousseau, et al. N Engl J Med. 2025 Jun 19;392(23):2297-2308

Among patients with mismatch repair-deficient (dMMR), locally advanced rectal cancer, neoadjuvant checkpoint blockade eliminated the need for surgery in a high proportion of patients. Whether this approach can be extended to all early-stage dMMR solid tumors, regardless of tumor site, is unknown. We conducted a phase 2... Read More

24 Mar, 2026

Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy

Suzanne L Topalian, Patrick M Forde, Leisha A Emens,et al.   Cancer Cell. 2023 Sep 11;41(9):1551-1566

Among new treatment approaches for patients with cancer, few have accelerated as quickly as neoadjuvant immune checkpoint blockade (ICB). Neoadjuvant cancer therapy is administered before curative-intent surgery in treatment-naïve patients. Conventional neoadjuvant chemotherapy and radiotherapy are primarily intended t... Read More

24 Mar, 2026

Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization

Douglas B. Johnson, Amin H. Nassar, Ayesha Aijaz,et al. Nat Rev Clin Oncol 2026 Feb 18.

Anti-PD-L1 antibodies have transformed cancer treatment and are increasingly being used in patients with early-stage malignancies including in the adjuvant and neoadjuvant settings. In this Review, we explore the optimal use of anti-PD-L1 antibodies in the adjuvant and perioperative settings, using examples from melano... Read More

24 Mar, 2026

Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice

Ivone U S Leong, Claudia P Cabrera, Valentina Cipriani, et al.J Clin Oncol. 2025 Feb 20;43(6):682-693

As part of the 100,000 Genomes Project, we set out to assess the potential viability and clinical impact of reporting genetic variants associated with drug-induced toxicity for patients with cancer recruited for whole-genome sequencing (WGS) as part of a genomic medicine service. We identified clinically relevant PGx v... Read More

24 Mar, 2026

Germline Testing in Patients with Breast Cancer: ASCO–Society of Surgical Oncology Guideline

Isabelle Bedrosian, Mark R. Somerfield, Maria Isabel Achatz, et al. J. Clin Oncol 2024 Feb 10;42(5):584-604

An ASCO–Society of Surgical Oncology (SSO) panel convened to develop recommendations based on a systematic review and formal consensus process. Forty-seven articles met eligibility criteria for the germline mutation testing recommendations: 18 for the genetic counseling recommendations. BRCA1/2 mutation testing should ... Read More

24 Mar, 2026

The Potential of Genetics in Identifying Women at Lower Risk of Breast Cancer

Alexandre Bolze, Elizabeth T. Cirulli, Catherine Hajek,. JAMA Oncol. 2024;10(2):236-239

Genetic information is not being used to identify women at lower risk of breast cancer or other diseases in clinical practice. With the new US Preventive Services Task Force guidelines lowering the age for mammogram screening for all, there is a potential benefit in identifying women at lower risk of disease who may de... Read More

24 Mar, 2026

Cost-Effectiveness of Population-Based Multigene Testing for Breast and Ovarian Cancer Prevention

The current method of BRCA testing for breast and ovarian cancer prevention, which is based on family history, often fails to identify many carriers of pathogenic variants. Population-based genetic testing offers a transformative approach in cancer prevention by allowing for proactive identification of any high-risk in... Read More

24 Mar, 2026

Genomic Screening at a Single Health System

Juliann M Savatt 1, Melissa A Kelly 1, Amy C Sturm 1 2, Cara Z McCormick . JAMA Netw Open. 2025 Mar 3;8(3):e250917

Completion of the Human Genome Project prompted predictions that genomics would transform medicine, including through genomic screening that identifies potentially medically actionable findings that could prevent disease, detect it earlier, or treat it better. However, genomic screening remains anchored in research and... Read More

24 Mar, 2026

Geno4ME Study: implementation of whole genome sequencing for population screening in a large healthcare system

Isabelle A. Lucas Beckett, Kate R. Emery, Josiah T. Wagner. npj Genomic Medicine | (2025) 10:50

Genomic medicine is now at a point where increased sequencing speed, cost reduction, and scalable cloud platforms can enable population-scale clinical sequencing. As 88% of US hospitals are community hospitals, integrating genomics into community healthcare represents a significant opportunity for greater genomic acces... Read More

24 Mar, 2026